MEMeral Ilgaz Ergin

Meral Ilgaz Ergin

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Meral Ilgaz Ergin has a total of 50 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • CMV reactivation after autologous stem cell transplantation: exploratory associations with transfusion burden and pre-transplant IMID exposure

    by Meral Ilgaz, Selma Gökahmetoğlu, Mehmet Çelik, Leylagül Kaynar

    Aims: To evaluate the incidence of CMV reactivation and disease after autologous stem cell transplantation (ASCT), identify risk factors with particular focus on erythrocyte transfusion burden and immunomodulatory drug (IMID) exposure, and determine high-risk subgroups warranting intensified surveillance. Methods: Retrospective analysis of 188 CMV-seropositive ASCT recipients at Erciyes University between 2007–2016. CMV PCR was performed twice weekly for the first 100 days. Erythrocyte suspension (ES) and platelet suspension (PS) were analysed separately alongside combined transfusion burden. Fisher exact and chi-square tests were used (SPSS v16.0). Results: CMV reactivation occurred in 44 patients (23.4%); 40 (90.9%) had asymptomatic DNAemia and 4 (9.1%) developed CMV disease. All reactivation events occurred within day +46. Refractory/progressive disease was associated with higher reactivation rates (50.0% vs 21.9%; p=0.056). ES ?6 units was strongly associated with CMV reactivation (62.5% vs 24.0%; odds ratio [OR] 5.28, 95% confidence interval [CI]: 1.20–23.18; p=0.028), while PS alone was not (p=0.429). IMID exposure was significantly protective in multiple myeloma (MM) patients (9.5% vs 27.4%; p=0.022) and the overall cohort (9.3% vs 27.6%; p=0.013). The protective effect was independent of IMID timing (pre-transplant 10.5% vs post-transplant 9.5%; p=1.000). Conditioning regimen was not associated with CMV reactivation (p=0.863). Conclusion: Refractory disease and high erythrocyte transfusion burden are the strongest predictors of CMV reactivation after ASCT. ES is the primary transfusion-related determinant. The timing-independent protective effect of IMIDs suggests a durable NK-cell mediated immunological mechanism. Risk-stratified CMV monitoring is recommended for high-risk subgroups.

  • Open Access

    Real-world effectiveness and safety of ruxolitinib in myelofibrosis: a multicenter cohort study (CHART-MF)

    by Pinar Tarkun, Mehmet Sonmez, Osman Yokus, Ayse Tulin Firatli Tuglular, Zubeyde Nur Ozkurt, Guray Saydam, Selami Kocak Toprak, Volkan Karakus, Tuba Hacibekiroglu, Ahmet Muzaffer Demir, et al.


  • Open Access

    A rare blood transfusion complication: Bacillus thermoamylovorans bacteremia and diffuse pustular rash

    by Kerim Çayıröz, Mert Tokatlı, Pelin Narli, Meral Ilgaz Ergin, Ümit Yavuz Malkan, Meliha Çağla Sönmezer, Oğuz Abdullah Uyaroğlu

    Bacillus thermoamylovorans is a species of bacillus that causes structural defects in milk by contaminating milk with its heat-resistant spores. We report a case of diffuse pustular rash on the extremities and bacillus thermoamylovorans bacteremia in blood culture after erythrocyte suspension replacement. On admission, his acute phase reactants were elevated and he had a generalized rash. After appropriate antibiotherapy, his lesions regressed almost completely. There is no case report of blood transfusion-associated bacillus thermoamylovorans bacteremia in the literature. This case is presented to contribute to the literature to show that Bacillus thermoamylovorans bacteremia may play a role in the etiology of pustular rash and infectious reactions associated with blood transfusion.

  • Open Access

    Ponatinib-induced dilated cardiomyopathy: a case report

    by Mert Tokatlı, Neslihan Nisa Gecici, Meral Ilgaz Ergin, Gülay Mart, Elifcan Aladağ Karakulak, Uğur Nadir Karakulak, İbrahim Celalettin Haznedaroglu

    Ponatinib is a third-generation tyrosine kinase inhibitor with potent efficacy in the treatment of acute and chronic leukemia. Despite having an effective and sustained activity in all BCR-ABL1 mutations, it may cause cardiovascular adverse effects. Here we report a 56-year-old male patient with Chronic myeloid leukemia and no prior cardiac disorder who developed acute heart failure under ponatinib treatment. Guideline-recommended medical treatment for heart failure was initiated. Coronary angiography to exclude ischemic heart disease revealed no coronary stenosis. Cardiac magnetic resonance imaging showed findings consistent with non-ischemic dilated cardiomyopathy. After interruption of ponatinib treatment, cardiac evaluation showed improvement in left ventricular ejection fraction. Patients on Ponatinib therapy should be closely monitored for signs and symptoms of heart failure.

  • Open Access

    An Unusual Cause of Bilateral Adrenal Incidentaloma: A Case Report of Primary Adrenal Lymphoma

    by Mert Tokatli, Neslihan Nisa Geci̇cİ, Meral Ilgaz Ergi̇n, Umit Yavuz Malkan, Oguz Abdullah Uyaroglu

    Primary adrenal lymphoma (PAL) is an extremely rare among the causes of adrenal incidentaloma. Most were diagnosed with adrenal insufficiency and B symptoms (unexplained weight loss, night sweats, fever). This article presented a 57-year-old woman who was investigated for bilateral adrenal masses found incidentally on computed tomography (CT). Physical examination and laboratory tests revealed no evidence of adrenal insufficiency or B symptoms. Only 24-hour urinary metanephrine and normetanephrine excretion were increased. Tumour F-18 fluorodeoxyglucose (FDG) positron emission tomography (PET/CT) scan showed the greatest dimension was 14 cm in the left adrenal mass and the maximum standardized uptake value (SUV max) was 26.1 (relative to mean SUV in the normal liver parenchyma, which was 2). An adrenal biopsy was performed after taking adequate precautions against the possibility of a catecholamine crisis. Histopathology revealed high-grade B-cell lymphoma. Bone marrow involvement and brain metastasis were not observed. She received the R-EPOCH (rituximab, etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin) regimen and intrathecal methotrexate therapy as central nervous system prophylaxis. The patient responded well to treatment, and close clinical follow-up continues. PAL should always be considered when a bilateral adrenal mass is detected.